glp 1 and bulimia New hope for binge eating bulimia: GLP-1 drugs could be the key Neurobiological Mechanisms and Therapeutic Potential

BPC-157 accelerates natural healing processes rather than creating supernatural regeneration

Cardiovascular outcome trials for liraglutide, semaglutide, and dulaglutide demonstrated modest blood pressure reductions alongside reduced major adverse cardiovascular events

These include: Enhanced glucose-dependent insulin secretion Suppressed glucagon secretion Slowed gastric emptying Increased satiety via central hypothalamic action This results in both glycaemic improvement and clinically meaningful weight loss

As a result, semaglutide supports weight loss , improves blood sugar management , and helps reduce the risk of cardiovascular events